Precision Neuroscience and UChicago Medicine announced on April 30 the launch of a clinical research partnership focused on AI-driven sensorimotor function and neuroprosthetics, expanding Precision’s clinical research network to a new academic medical centre. The collaboration is led on the UChicago side by Dr. Peter Warnke, director of stereotactic and functional neurosurgery and professor of neurological surgery at UChicago Medicine. The partnership uses Precision’s Layer 7 Cortical Interface, the company’s high-density microelectrode array that received FDA 510(k) clearance for continuous neural data capture at high resolution for up to thirty days. BioSpace and MassDevice both carried the announcement.
The partnership is the second material Precision Neuroscience institutional move announced in 2026, following the company’s January integration with Medtronic’s StealthStation surgical navigation system. Together the two announcements describe Precision’s commercial-research strategy, which positions Layer 7 as both a clinical research instrument distributed through academic medical centres and a surgical-platform component embedded inside incumbent medtech infrastructure.
What the partnership does
The UChicago Medicine collaboration focuses on two interconnected research strands. The first is AI-driven sensorimotor function decoding, which uses Layer 7’s high-resolution intraoperative neural recordings to study how the cortex plans and executes physical movement. The second is neuroprosthetic development, applying the resulting decoder algorithms toward assistive technologies for patients with motor impairment. Warnke framed the technical advance directly: “With Precision’s BCI technology, our team can now capture rich neural data without damaging the brain, giving us new ways to study how it understands and generates movement.”
The partnership extends Layer 7’s clinical reach into a major US academic medical centre with substantial functional neurosurgery volume. UChicago Medicine performs a high case load of stereotactic and functional procedures, including deep brain stimulation implantation, epilepsy surgery, and tumour resections that involve cortical mapping. Each of those procedures creates a clinical window in which Layer 7’s intraoperative recording can be deployed, generating the kind of high-resolution neural data that Precision’s commercial pitch depends on.
Layer 7’s positioning
Layer 7 is a flexible thin-film array containing 1,024 electrodes deployed on the cortical surface. Layer 7 reads neural activity from the surface without breaching the cortex itself, which positions it differently from penetrating-array competitors like Neuralink, Synchron, or Paradromics. Precision received FDA 510(k) clearance for the device, and Layer 7 cleared peer-reviewed publication in April with the first intraoperative speech and movement decoding data, which we covered at the time.
The device’s commercial frame is hybrid: it ships into clinical research at academic medical centres (the UChicago Medicine partnership being the latest), and it embeds into Medtronic’s StealthStation surgical navigation system for use during functional neurosurgery cases. That hybrid distribution model is rare in BCI. Most companies in the space are pursuing either pure direct-to-clinic medical-device commercialisation (Synchron, Paradromics with Connect One) or consumer-platform licensing (Neurable with HyperX). Precision is operating in both research-instrument and embedded-surgical-platform lanes simultaneously.
What this signals
Two threads worth tracking from the UChicago partnership. First, Precision’s clinical research network is becoming the company’s data moat. Each academic medical centre integration creates a pipeline of intraoperative neural recordings that train the company’s decoding algorithms. The volume and diversity of that data is what differentiates Precision’s eventual commercial product from competitors with smaller research-site footprints. Second, the partnership signals UChicago Medicine’s positioning as an institutional BCI research site. UChicago is now formally on Precision’s research-network map, and the institution gains access to a working high-density cortical interface for active research use.
The UChicago announcement is part of a broader pattern in 2026 of clinical-stage BCI companies deepening their academic medical centre relationships. CorTec’s stroke trial runs at Harborview through the University of Washington’s NIH-funded grant. Motif Neurotech, which received its first FDA IDE last week, will run its depression trial at academic sites once its protocol is registered. Synchron’s COMMAND study runs across multiple US academic centres. The infrastructure layer of clinical-stage BCI is consolidating around academic medical centre partnerships, and Precision Neuroscience is one of the more active companies building that footprint.